The National Comprehensive Cancer Network unveiled its first set of "evidence blocks" that include cost information on oncology drugs; this first round focuses on chronic myelogenous leukemia (CML) and multiple myeloma. Drugs from Bristol-Myers Squibb ($BMY), Novartis ($NVS), Johnson & Johnson ($JNJ), and Celgene ($CELG), among others, were assessed on efficacy, safety and affordability. More from FiercePharmaMarketing